Since glutamate and its NMDA receptor are involved in different types of epilepsy, pharmacological inhibition of this receptor or even gene expression suppression, particularly the GluN1 subunit, may offer protection against epileptic seizures, which reinforces the role of this receptor in epileptogenesis as well as in the potential treatment of TLE [11,26]. The gene discussed is GRIN1; the disease is epilepsy.